Efficacy and safety of eptifibatide in patients with acute coronary syndrome
Phase 2
Recruiting
- Conditions
- acute coronary syndrome.Other acute ischemic heart diseases(http://ap
- Registration Number
- IRCT20230805059045N1
- Lead Sponsor
- Rasht University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 156
Inclusion Criteria
All patients over 18 years old that have below characteristics
patient with acute coronary syndrome
patient treated with eptifibatide during angioplasty based on the diagnosis of the attending physician
Exclusion Criteria
If a patient with thrombocytopenia (platelets below 100,000)
bleeding (gastrointestinal, cerebral, pulmonary)
a history of intracranial events (neoplasm, arteriovenous malformation, cerebral aneurysm)
severe renal dysfunction (creatinine clearance below 50)
patients for whom Fibrinolytics have been prescribed in the last 24 hours
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy and safety of reduced dose compared to standard eptifibatide in patients with acute coronary syndrome. Timepoint: Check the results after 90 days. Method of measurement: Efficacy and safety of the reduced dose compared to the standard eptifibatide in patients with acute coronary syndrome is how to check the mechanical outcomes after 90 days through echocardiography.
- Secondary Outcome Measures
Name Time Method